PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level

[1]  S. Jason,et al.  Neuroblastoma , 2018, Definitions.

[2]  S. Dixon,et al.  p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. , 2018, Cell reports.

[3]  Ido D. Weiss,et al.  CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways. , 2018, Cancer research.

[4]  G. Ghanem,et al.  PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies , 2017, Cancers.

[5]  J. Maris,et al.  11q deletion in neuroblastoma: a review of biological and clinical implications , 2017, Molecular Cancer.

[6]  Paolo Fortina,et al.  Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines , 2017, Scientific Data.

[7]  K. Wiman,et al.  APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase , 2013, Cell Death & Disease.

[8]  J. Crown,et al.  Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer? , 2017, International journal of cancer.

[9]  P. Raman,et al.  Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.

[10]  K. Cole,et al.  Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma , 2016, Clinical Cancer Research.

[11]  B. Jean-Claude,et al.  Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status , 2016, Oncotarget.

[12]  G. Lozano,et al.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. , 2016, Cold Spring Harbor perspectives in medicine.

[13]  S. Lehmann,et al.  Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells , 2016, British journal of haematology.

[14]  Ansar Karimian,et al.  Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. , 2016, DNA repair.

[15]  J. Mora,et al.  Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression , 2016, Oncotarget.

[16]  F. Chibon,et al.  PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53 , 2015, BMC Cancer.

[17]  P. Raman,et al.  Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma , 2015, Clinical Cancer Research.

[18]  Jianbiao Zhou,et al.  PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms , 2015, Oncotarget.

[19]  A. Hallberg,et al.  APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells , 2015, Cell Death and Disease.

[20]  J. Maris,et al.  Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism , 2015, Oncotarget.

[21]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[22]  J. Joseph,et al.  The CXCR4/CXCR7/CXCL12 Axis Is Involved in a Secondary but Complex Control of Neuroblastoma Metastatic Cell Homing , 2015, PloS one.

[23]  G. Descamps,et al.  PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. , 2014, Blood.

[24]  O. Delattre,et al.  Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells , 2014, Oncotarget.

[25]  Tao Liu,et al.  Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 , 2014, Oncotarget.

[26]  G. Barone,et al.  MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. , 2014, Current drug targets.

[27]  William A Weiss,et al.  Neuroblastoma and MYCN. , 2013, Cold Spring Harbor perspectives in medicine.

[28]  K. Wiman,et al.  APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase , 2013, Cell Death and Disease.

[29]  M. Saha,et al.  PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa , 2013, Molecular Cancer Therapeutics.

[30]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[31]  Jean-Yves Blay,et al.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.

[32]  G. Juliusson,et al.  Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[34]  Joost Schymkowitz,et al.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. , 2011, Nature chemical biology.

[35]  C. Maki,et al.  Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 , 2011, Oncogene.

[36]  F. Westermann,et al.  Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3 , 2011, Molecular Cancer Therapeutics.

[37]  T. Gerds,et al.  PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53 , 2011, Clinical Cancer Research.

[38]  P. Hainaut,et al.  Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis , 2010, Oncogene.

[39]  Jan Bergman,et al.  PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. , 2009, Cancer cell.

[40]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[41]  H. Nakshatri,et al.  Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion , 2007, Oncogene.

[42]  F. Speleman,et al.  Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. , 2006, Cancer research.

[43]  S. Berg,et al.  MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death , 2006, Molecular Cancer Therapeutics.

[44]  K. Wiman,et al.  PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis , 2005, Oncogene.

[45]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[46]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[47]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[48]  J. Lunec,et al.  Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. , 2001, Cancer research.

[49]  P. McKenzie,et al.  Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  C. Thiele.  Neuroblastoma Cell Lines , 1998 .

[51]  P. Paty,et al.  Mitochondrial Proliferation and Paradoxical Membrane Depolarization during Terminal Differentiation and Apoptosis in a Human Colon Carcinoma Cell Line , 1997, The Journal of cell biology.

[52]  G. Melino,et al.  Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells , 1993, FEBS letters.